Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults with Relapsed or Refractory Osteosarcoma
Protocol ID
E7080-G000-230 (OLIE)
Disease (Sub Disease)
Solid tumours (Osteosarcoma)
Diagnosis Stage
Relapsed/ refractory
Sponsor
Eisai Inc.
Collaborators
Merck Sharp & Dohme Corp.
Links
Trial Status
Closed to Recruitment
Trial Close Date
16/11/2021
Study Type
Treatment
Phase
Phase 2
Age Eligibility
2 Years to 25 Years
International registry ID's
NCT04154189
| Study Title | A Multicenter Open-label Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children Adolescents and Young Adults with Relapsed or Refractory Osteosarcoma |
|---|---|
| Protocol ID | E7080-G000-230 (OLIE) |
| Disease (Sub Disease) | Solid tumours (Osteosarcoma) |
| Diagnosis Stage | Relapsed/ refractory |
| Sponsor | Eisai Inc. |
| Collaborators | Merck Sharp & Dohme Corp. |
| Links | https://clinicaltrials.gov/ct2/show/NCT04154189 |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 23/03/2020 |
| Trial Close Date | 16/11/2021 |
| Study Type | Treatment |
| Phase | Phase 2 |
| Age Eligibility | 2 Years to 25 Years |
| International registry ID's | NCT04154189 |